Clinical Trial: A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma

U.S., Sept. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07797881) titled 'A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma' on Aug. 27.

Brief Summary: This Phase II study is a clinical trial exploring the efficacy and safety of BL-B01D1 with or without PD-1 monoclonal antibody in patients with high-risk locally advanced nasopharyngeal carcinoma.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Nasopharyngeal Carcinoma (NPC)

Intervention: DRUG: BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG: PD-1 monoclonal antibody

Administration by intravenous infusion for a cycle of ...